Category: Uncategorized

KUALA LUMPUR, Nov 22 (Bernama) — H2SITE has successfully validated the first ammonia cracker to produce high-purity hydrogen for onboard power generation using a polymer electrolyte membrane (PEM) fuel cell.

In a statement, the company said an integrated membrane reactor has been installed and operated on board of the BERTHA B supply ship, sailing the shores of the Gulf of Biscay.

“Our innovative membrane reactor technology not only brings an improvement in system efficiency but also reduces the footprint of the installation. This is especially important in applications where space is limited, such as onboard a vessel.

“We have focused our design efforts on minimising the ammonia consumption, which will be key for the scale up to suit higher power output units,” said H2SITE Technical Director, Jose Medrano.

Maritime transport is responsible for two per cent of global greenhouse gas emissions, presenting significant potential for emission reduction by transitioning from hydrocarbons to green fuel options, such as hydrogen.

Ammonia cracking is gaining traction as a potential hydrogen carrier for onboard applications and it can be used directly in engines, or can be cracked into hydrogen and used in fuel cells. Before hydrogen is used, purification is necessary, especially if traces of ammonia are present.

H2SITE’s membrane reactors make sure all the ammonia is transformed, while delivering a high purity hydrogen to the fuel cell in a single process step. During navigation, as part of the H2OCEAN project, H2SITE’s cracker has successfully powered the ship’s auxiliary services.

This achievement was made possible by working together with players active in the maritime decarbonisation segment such as Zumaia Offshore, Erhardt Offshore, Ajusa, and TECNALIA, along with the participation of Enagas and ABS.

This project is a stepping stone for H2SITE in the decarbonisation of maritime transport.

Based in Spain, H2SITE was established in 2020 and possesses exclusive technology for reactors and separators, facilitating the conversion of various feedstocks into hydrogen.

— BERNAMA

KUALA LUMPUR, Nov 21 (Bernama) — OPEN Health is bringing together experts in strategic patient innovation and engagement, deepening the organisation’s existing commitment to building patient-first solutions.

“I am excited to bring together our global experts to focus on engagement with patients, caregivers, community leaders, and advocacy groups. Together, we will use the patient voice to improve life-changing treatments across the globe,” said OPEN Health Patient Engagement President, Cherie Myatt in a statement.

Meanwhile, its Chief Medical Officer, Dr Annemarie Clegg said: “By working as one, united team, we can better leverage our respective talents and methodologies to unlock patient engagement opportunities across the product life cycle and drive more effective engagement solutions.”

The organisation is combining the strength, expertise, and proven track record of the Px Group, a division of the CM Group which was acquired in 2022, and its own patient engagement team into a unified global patient communications, patient research and creative patient engagement partner.

The combined team will be led by Myatt who is also CM Group co-founder; alongside Senior Vice President, Alexandra Dubois; Registered Health Psychologist and Cognitive Behavioural Therapist, Dr Sumira Riaz; and Patient Centricity Global Lead, Gavin Jones.

Collaborating with more than 1,300 global OPEN Health experts, the Patient Engagement team provides a wide range of solutions to address specific challenges for clients.

Its full suite of solutions includes strategy, insights & market research; health psychology & behavioural science; patient content & storytelling; as well as Patient Engager programmes and advocacy engagement.

OPEN Health is a preeminent global provider of consulting, Health Economics and Outcomes Research (HEOR) and market access, patient engagement, and scientific and creative communications services.

— BERNAMA

KUALA LUMPUR, Nov 21 (Bernama) — The International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital and Harvard Medical School, launched a six-month nationwide programme to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counselling, to help further genomic medicine’s global promise.

According to a statement, this training programme is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.

The comprehensive partnership between iCGD, Mass General Brigham, and the Department of Health – Abu Dhabi will help advance life sciences and health care outcomes globally while leveraging the advanced genomics capabilities of the Emirate.

Genomic medicine, also known as precision medicine, offers transformative opportunities to reshape health care and public health from a ‘one size fits all’ approach to one utilising an individual’s genetic profile, informing their personalised care pathway from prevention and diagnosis, to treatment of diseases and the development of novel and more effective drugs.

With an emphasis on screening, diagnosis, and treatment of a wide spectrum of genetic conditions, clinicians will become deft with the necessary knowledge and skills to address genetic and genomic challenges in a clinical setting.

Additionally, the programme ensures the successful execution of the Emirati Genome Program, bringing precision medicine to the forefront of public health policy formulation and implementation across the UAE.

Delivered by globally recognised Harvard-affiliated experts within the Mass General Brigham system and elsewhere, the programme will enhance the knowledge and expertise of Emirati physicians, who will then be able to further incorporate the latest innovations in genomic medicine and genetic counselling into the clinical care of patients.

The iCGD designed the programme to specifically address the public health needs of the UAE.

By integrating clinical data and genetic information, healthcare providers can improve population screening, diagnosis, prognosis, risk management, and in some cases, offer new and innovative targeted therapy for conditions including cardiovascular diseases, lipid disorders, diabetes, among many other clinically complex morbidities.

— BERNAMA

KUALA LUMPUR, Nov 21 (Bernama) — Nanjing IASO Biotechnology Co Ltd (IASO Bio) made its debut at the Sixth China International Import Expo (CIIE) with FUCASO, the world’s first fully-human chimeric antigen receptor T-cell (CAR-T).

In a statement, the company said it has also entered into a strategic partnership with several international medical institutions, bringing hope for cure to multiple myeloma (MM) patients worldwide.

The China National Medical Products Administration (NMPA) approved the marketing of FUCASO’s Equecabtagene Autoleucel Injection for the treatment of adult patients with relapsed or refractory multiple myeloma (r/rMM), on June 30.

Meanwhile, the injection has received the Orphan Drug Designation, as well as the Regenerative Medicine Advanced Therapy and Fast Track Designations from the United States (US) Food and Drug Administration, and has been approved for clinical trials in the US.

A single infusion of FUCASO can lead to lasting and deep remission with a favourable safety profile in patients with r/rMM who have failed multiple lines of therapy.

Due to its unique design, FUCASO, as a fully-human CAR-T therapy, is able to persist in patients for a longer period of time, offering hope for overcoming the challenging problem of relapsed MM.

FUCASO has attracted patients from numerous countries around the world to seek treatment in Chinese hospitals in just four months since its approval for marketing in China.

These hospitals have a world-leading level of full-process management in CAR-T therapy, in addition to the cost of treatment with FUCASO in China is significantly lower than that of similar products in Europe and America, which has benefitted more patients worldwide.

— BERNAMA

AsiaNet 100501

^{The launch ceremony}

FUZHOU, China, Nov. 20, 2023 /Xinhua-AsiaNet/–

The 8th Maritime Silk Road (Fuzhou) International Tourism Festival kicked off in Fuzhou, Fujian Province, China on 17th November. The festival in Fuzhou is sponsored by the Ministry of Culture and Tourism of the People’s Republic of China and the People’s Government of Fujian Province. It is hosted by the Department of Culture and Tourism of Fujian Province and Fuzhou Municipal People’s Government.

The festival showcases Fuzhou’s active participation in the Belt and Road Initiative by inviting nearly 500 guests to take part in related activities in the city. These guests include representatives from international organisations, the World Tourism Alliance, the International Mountain Tourism Alliance, and representatives of friendly cities of co-building countries, all working together to enhance the impact of the Maritime Silk Road (Fuzhou), according to Fuzhou Municipal Bureau of Culture and Tourism.

This year’s festival is emphasising international characteristics, unique aspects of the Maritime Silk Road, and the fusion of culture and tourism. The main events include the festival’s launch ceremony and cultural tourism dialogue, the Fujian Tourism Expo 2023, and the grand cultural and tourism experience event “Maritime Silk Road-Themed Wonders Night”, showcasing a diverse array of Fuzhou’s culture as an international brand. The festival highlights distinctive aspects of Fuzhou’s culture, including the historical and cultural significance of Yantai Mountain, hot springs, Fujian cuisine, ancient houses, and intangible cultural heritage, all contributing to showcasing the charm of Fuzhou.

The Maritime Silk Road (Fuzhou) International Tourism Festival marks a significant milestone for Fujian Province and Fuzhou City in their efforts to comprehensively develop and construct a central area that will play a key role in the “21st Century Maritime Silk Road”. The festival has been held for seven consecutive years since it began in 2015, offering a new platform for regional cooperation, promotion, and collaboration among participating countries to learn from and benefit each other. It has evolved into an internationally influential tourism conference.

Source: Fuzhou Municipal Bureau of Culture and Tourism

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=443298

   Caption: The launch ceremony